Helius Medical Technologies, Inc. Comments on Unusual Market Activity
January 05 2021 - 04:05PM
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius”
or the “Company”), a neurotech company focused on neurological
wellness, is issuing this news release in light of unusual trading
activity related to the shares of Class A Common Stock of Helius
(the "Shares") on the Toronto Stock Exchange and The Nasdaq Capital
Market. In view of such activity, The Nasdaq Capital Market and the
Investment Industry Regulatory Organization of Canada (IIROC) on
behalf of the Toronto Stock Exchange contacted the Company in
accordance with their usual practice. While Helius does not
normally comment on market activity, Helius confirms that it is not
aware of any undisclosed material change in the business,
operations or affairs of Helius that would account for the recent
increase in trading activity, and related increase in trading
price, of the Shares on the Toronto Stock Exchange and The Nasdaq
Capital Market. Helius notes that this afternoon it is first making
available an investor presentation, by furnishing the slides on a
Current Report on Form 8-K, in connection with its planned
participation at investor conferences in January, which conference
participation was announced by press release on January 4, 2021.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on
neurological wellness. The Company’s purpose is to develop, license
and acquire unique and non-invasive platform technologies that
amplify the brain’s ability to heal itself. The Company’s first
commercial product is the Portable Neuromodulation Stimulator
(PoNS™). For more information,
visit www.heliusmedical.com.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNS™) is authorized
for sale in Canada as a class II, non-implantable, medical device
intended as a short term treatment (14 weeks) of gait deficit due
to mild and moderate symptoms from multiple sclerosis (MS), and
chronic balance deficit due to mild-to-moderate traumatic brain
injury (mmTBI) and is to be used in conjunction with physical
therapy. The PoNS™ is an investigational medical device in the
United States, the European Union (“EU”), and Australia (“AUS”).
The device is currently under review for clearance by the FDA. It
is also under premarket review by the AUS Therapeutic Goods
Administration. PoNS™ is currently not commercially available in
the United States, the European Union or Australia.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies,
Inc.Mike Piccinino, CFAinvestorrelations@heliusmedical.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2023 to Mar 2024